Cardiomyopathy secondary prevention

Cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Guidelines
2023 ESC Guideline Recommendations
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
Case Studies
Case #1
Cardiomyopathy secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cardiomyopathy secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cardiomyopathy secondary prevention
CDC on Cardiomyopathy secondary prevention
Cardiomyopathy secondary prevention in the news
Blogs on Cardiomyopathy secondary prevention
Directions to Hospitals Treating Cardiomyopathy
Risk calculators and risk factors for Cardiomyopathy secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub, MD; Edzel Lorraine Co, DMD, MD[2]

ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation.